Novartis acquires Kedalion Therapeutics and its ocular delivery platform
The company intends to develop the AcuStream technology for potential use with its current and future front-of-eye therapies, which may include lifitegrast ophthalmic solution for the treatment of dry eye disease.
Novartis has purchased Kedalion Therapeutics and its AcuStream technology, the company announced on June 30.
The AcuStream platform is a preservative-free, electromechanical ocular delivery service with the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye, according to the company news release.
Novartis currently intends to expand AcuStream for use with both future and existing front-of-eye therapies, including Xiidra (lifitegrast ophthalmic solution) 5%, which is used for the treatment of dry eye disease (DED).
Kedalion Therapeutics is a clinical-stage, venture-funded ophthalmic drug company based in California. The company announced the completion of its Series B funding—led by Novartis—in November 2021.
The funding included an exclusive option to acquire Kedalion and its AcuStream technology, according to the release.
